Company
AOBiome
Also known as AOBiome LLC
- Business model
- B2B
- Legal name
- AOBiome LLC
Record updated 29 September 2026
About
AOBiome is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other diseases. Our proprietary product candidates harness a strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria, or AOB, a human commensal with well-understood and well-characterized biochemical properties that are critical to human health. We believe that the application of AOB has the potential to restore critical biological and biochemical processes through the symbiotic relationship between humans and this naturally-existing bacteria to address significant clinical need at various stages of disease. We have six ongoing clinical programs in acne vulgaris, or acne, atopic dermatitis, or eczema, rosacea, allergic rhinitis, migraine and hypertension, and multiple ongoing preclinical programs, including ones addressing pulmonary and gastrointestinal disorders.
Funding snapshot
- Total raised
- $3.7MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $2.5M2015-09-01
Funding rounds
- Round, 2015
- $2.5M2015-09-01, SEC form D sold, 2 investors
- Round, 2014
- $577K2014-08-18, SEC form D sold, 13 investors
- Round, 2013
- $630K2013-01-19, SEC form D sold, 9 investors